DualityBio Inc. (HKEX: 09606) announced on August 28 that it has entered a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates (ADCs) built on DualityBio’s proprietary DUPAC payload platform. Unlike several recent biotech licensing deals that disclosed no financial terms, this one comes with real numbers: DualityBio will receive a $45 million upfront payment, is eligible for more than $1 billion in aggregate milestone payments across the collaboration’s programs, and will earn tiered royalties on any resulting product sales.

What DUPAC Is

An ADC works by chemically linking a cancer-targeting antibody to a cell-killing drug payload, letting the antibody guide the toxic payload specifically to tumor cells rather than exposing the whole body to it the way traditional chemotherapy does. DUPAC, short for DualityBio Unique Payload Antibody Conjugate, is one of four ADC platforms DualityBio has built and is focused specifically on new payload chemistries, including three named components, DUP5, DUP9, and DUP10, each working through a distinct mechanism to kill cancer cells rather than variations on the same mechanism.

The Problem DUPAC Is Meant to Solve

The rationale behind DUPAC centers on a problem emerging across the ADC field: a class of payload called topoisomerase inhibitors, used in some of the most successful approved ADCs, is increasingly being used earlier in cancer treatment, which means more patients are eventually progressing on that specific payload class and running out of options built on the same mechanism. DualityBio says DUPAC’s payloads are designed to retain activity against tumors that no longer respond to topoisomerase inhibitor-based ADCs, giving oncologists a next option built on different underlying chemistry rather than a variation of the same one.

The Evidence So Far

The preclinical evidence behind this claim comes from data DualityBio has presented at named scientific conferences, including AACR’s 2025 and 2026 annual meetings and the AACR-NCI-EORTC International Conference in 2025, covering DUP5-based and DUP9-based ADCs tested in tumor models that are relatively insensitive to topoisomerase inhibitor payloads, along with tolerability data in non-human primates. Presenting specific, citable conference abstracts is a stronger form of evidence than an unpublished company claim, though it remains preclinical data from animal and lab models rather than results in human patients.

How the Deal Is Structured

Under the deal structure, DualityBio will lead early discovery and global clinical development work, generating ADCs against oncology targets that Genentech selects, using payloads from the DUPAC platform. Genentech receives an exclusive, worldwide license to whatever comes out of the collaboration and takes over all further clinical development and commercialization once each program completes Phase 1a testing, the earliest stage of human trials focused on safety rather than efficacy. That structure lets DualityBio focus its resources on the science and early trial work it is set up to do well, while Genentech absorbs the far larger costs of late-stage trials, regulatory filings, and global commercial launch if a program succeeds.

What the Companies Are Saying

DualityBio founder and CEO John Zhu described DUPAC as built specifically to help patients who become resistant to topoisomerase inhibitor-based ADCs, and framed the Genentech partnership as a way to combine DualityBio’s payload science with Genentech’s oncology development reach. Roche’s head of corporate business development, Boris Zaïtra, said the collaboration reflects Roche’s ongoing focus on next-generation targeted cancer medicines. Both statements describe the companies’ strategic reasoning for the deal rather than independently verified outcomes.

Part of a Broader Track Record

This is not DualityBio’s first out-licensing agreement; the company says it has previously struck similar collaborations with other global pharmaceutical and biotech companies, and it describes itself as running clinical trials across nearly 20 countries with more than 3,500 patients enrolled to date across its ADC pipeline. That track record, combined with a disclosed deal structure and real payment figures, gives this collaboration more concrete substance than a typical early-stage platform licensing announcement.

What’s Next

The deal also fits a broader pattern of large Western pharmaceutical companies licensing ADC technology from Chinese biotech companies in recent years, a trend driven by strong early clinical data coming out of China’s ADC sector and a general shortage of differentiated next-generation payload technology inside large pharma’s own pipelines. Under this agreement, DualityBio also retains three other ADC platforms outside the scope of this deal, DITAC, DIMAC, and DIBAC, meaning the company has additional technology it could still license separately to other partners or advance on its own. DualityBio’s release does not disclose which specific tumor types or how many total targets the Genentech collaboration will initially cover, and none are estimated here. This article covers a licensing and collaboration agreement and is not an investment recommendation.

Sources

Duality Biotherapeutics, Inc.: DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio’s DUPAC Novel-Payload Platform, PRNewswire, August 28, 2026.

Editorial Disclosure

This article is based on a press release issued by Duality Biotherapeutics, Inc. on August 28, 2026, distributed via PRNewswire. DualityBio trades on the Hong Kong Stock Exchange under the ticker 09606; Genentech is a member of the Roche Group. BioTech Stocks Daily was not compensated for this coverage. Preclinical data referenced in this article were presented at named scientific conferences as cited in the release; statements regarding the strategic rationale and expected benefits of the collaboration are forward-looking and involve risks and uncertainties, including the uncertainty of clinical success. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.